Barcetanib in Lupus Nephritis

Barcetanib phase three trial in Lupus nephritis. At 12 weeks, 70% people on the Barcetanib group achieve significant reduction in proteinuria versus 43%. And also when they adjust for lacida and complements also at 24 weeks as well,. So that's encouraging. But the population, I just know. Yeah, we'd like to see larger numbers and whatnot. We're not certain people are debating about today because there's only single-legis proteinuria in usually these days in terms of complete renal response rates.